FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2155-2156 May 22, 2003 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Baert, F. PubMed Citation

To the Editor: Baert et al. (Feb. 13 issue)¹ report the formation of antibodies to infliximab in 61 percent of patients with Crohn's disease treated episodically ("on demand") with infliximab. This rate is higher than the 10 to 15 percent incidence observed in previous trials in patients with Crohn's disease.^2,3,4 In the A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT) I study,⁵ the incidence of the formation of antibodies to infliximab was greatly reduced with the administration of an induction regimen at zero, two, and six weeks, followed by maintenance therapy every eight weeks . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.